// App-Quantinova.ai

e14579 : A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.

Researchers

Presenter

  • Shikhar Mehrotra

Principal Investigators

  • Carolyn D. Britten

  • Steve Hsukwo Chin

  • Mohamed L. Salem

  • Colleen Cloud

  • Michelle H. Nelson

  • Chrystal Paulos

  • Elizabeth Garrett-Mayer

  • Mark P. Rubinstein

  • Zihai Li

  • David J. Cole

Medical Centers

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Eli Lilly and Company, Carmel, IN

  • Tanta University, Tanta, Egypt

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Departments of Surgery and Microbiology & Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Medcl Univ of South Carolina, Charleston, SC

  • Medcl Univ of South Carolina, Charleston, SC

  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

Locations

  • United States

  • Egypt

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • Carcinoembryonic antigen

  • Human leukocyte antigen A2

  • Telomerase reverse transcriptase

Drug/Treatment

  • Poly-ICLC

  • TERT572Y

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01410968

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved